VBCN - July 2015 Volume 2, No 2

An inhaled formulation of levodopa (CVT-301) eased breakthrough motor symptoms in patients with Parkinson’s disease (PD) between standard levodopa doses in a phase 2 clinical trial.

Racial disparities in poststroke activities of daily living (ADL) limitations are not a result of prestroke activity limitations.

A retrospective review of pediatric emergency department data showed significant pain reduction when sodium valproate (VPA) was used in the second-line setting for the treatment of adolescent patients with migraine.

With worsening symptoms and increasingly unpredictable attacks, the burden for patients with secondary-progressive multiple sclerosis (MS) is undeniable, and studies have shown that accumulating levels of disability experienced by patients with MS have a direct impact on their quality of life.

A pragmatic review of literature has identified best practices for network meta-analyses (NMAs) of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis (RRMS).

A recent analysis of current evidence indicates that physicians can switch patients with relapsing-remitting multiple sclerosis (RRMS) from other disease-modifying therapies (DMTs) to teriflunomide (Aubagio) without worrying about a drop in efficacy or serious adverse events.

A new retrospective review of patients presenting with acute ischemic stroke has shown additional predictors of outcome independent of traditional assessment tools.

The FDA approved the Brio Neurostimulation System, an implantable deep brain stimulation device manufactured by St Jude Medical, St Paul, MN, to help reduce the symptoms of Parkinson’s disease and essential tremor.

The FDA has approved an expanded indication for topiramate extended-release capsules (Qudexy XR; Upsher Smith Laboratories, Inc).